Neil D. Gross: Neoadjuvant immunotherapy for advanced, resectable cutaneous squamous cell carcinoma

Neil D. Gross, The Director of Clinical Research in the Department of Head and Neck Surgery at MD Anderson Cancer Center, shared a post on X:

”Latest news on neoadjuvant immunotherapy for advanced, resectable cutaneous squamous cell carcinoma presented last week at the European Society for Medical Oncology 2024, showing durable improved survival at 29.4 months. MD Anderson Cancer Center is excited to launch HN014 NRG Oncology and TROG Cancer Research.”

Source: Neil D. Gross/X